ω-Agatoxin IVA TFA: Precision Cav2.1 Calcium Channel Blocker for Neuroprotection and Epilepsy Models

Executive Summary: ω-Agatoxin IVA TFA is a peptide toxin from funnel-web spider venom, supplied as a trifluoroacetate salt by APExBIO, that selectively blocks P/Q-type (Cav2.1) voltage-gated calcium channels with nanomolar potency (Yalcin Inan et al., 2024). It exhibits an IC50 of 1–2 nM for P-type Cav2.1 and up to 270.5 nM for Q-type variants containing the NP motif (APExBIO product page). In animal models, ω-Agatoxin IVA TFA suppresses epileptogenesis, prolongs seizure latency, reduces cleaved caspase-3 (apoptosis marker), and increases BDNF expression without impairing motor function (Yalcin Inan et al., 2024). The compound is validated for neuronal calcium current recording and synaptic transmission research, with established effective concentrations and dosing parameters. Its selectivity profile and neuroprotective actions make it a critical tool for investigating Cav2.1 channels in health and disease.

Biological Rationale

P/Q-type voltage-gated calcium channels (Cav2.1) are essential for neurotransmitter release at central synapses. Mutations in Cav2.1 channels are associated with epilepsy, episodic ataxia, and neurodegenerative disorders (Yalcin Inan et al., 2024). Elevated intracellular calcium via Cav2.1 contributes to excitotoxicity and apoptosis in neuronal injury models. Inhibition of Cav2.1 channels reduces pathological calcium influx, thereby limiting apoptosis and supporting neuronal survival (Yalcin Inan et al., 2024). Brain-derived neurotrophic factor (BDNF) is a key regulator of neuronal survival and plasticity; Cav2.1 inhibition by ω-Agatoxin IVA TFA upregulates BDNF expression in rodent models of epilepsy. These combined effects provide a mechanistic basis for using Cav2.1 calcium channel inhibitors in translational neuroscience and neuroprotection research.

Mechanism of Action of ω-Agatoxin IVA TFA

ω-Agatoxin IVA TFA is a 48-amino acid peptide that binds with high specificity to the pore region adjacent to the α1A subunit of Cav2.1 channels. It blocks P-type Cav2.1 channels with an IC50 of 1–2 nM (NP motif absent) and Q-type variants at up to 270.5 nM (NP motif present) (APExBIO). At 1 μM, it only weakly inhibits N-type (Cav2.2) channels and does not affect L-type (Cav1.x) or T-type (Cav3.x) channels (Yalcin Inan et al., 2024). By blocking Cav2.1, ω-Agatoxin IVA TFA inhibits calcium-dependent neurotransmitter release, including glutamate and GABA. This action disrupts epileptiform activity, attenuates excitotoxic apoptosis (as shown by reduced cleaved caspase-3), and elevates BDNF expression. The compound also modulates nicotinic activation in cardiac vagal neurons, indicating roles beyond the central nervous system (APExBIO).

Evidence & Benchmarks

• ω-Agatoxin IVA TFA prolongs seizure onset and suppresses epileptogenesis in dose-dependent fashion in rat PTZ-kindling and acute seizure models (Yalcin Inan et al., 2024).
• Reduces cleaved caspase-3 expression (apoptosis marker) in prefrontal cortex, striatum, hippocampus, and thalamic nucleus of rats after repeated administration (Yalcin Inan et al., Table 2).
• Increases BDNF expression in multiple brain regions, suggesting neuroprotective and regenerative capacity (Yalcin Inan et al., Fig. 3).
• Does not impair motor coordination as assessed by righting reflex and inclined plane tests (Yalcin Inan et al., Results).
• Validated effective in vitro concentrations: 100 nM–1 μM for neuronal current and synaptic transmission; in vivo: 0.01–1 nM (intracerebroventricular), 0.1–0.5 nM (intraperitoneal) for epilepsy models (APExBIO).

This article extends the detailed mechanistic discussion of "ω-Agatoxin IVA TFA: Precision Cav2.1 Calcium Channel Bloc..." by integrating validated in vivo neuroprotection and quantitative apoptosis data from recent peer-reviewed studies. For advanced troubleshooting and workflow strategies, see "ω-Agatoxin IVA TFA: Precision Tools for Cav2.1 Channel In...", which this article supplements with updated benchmark dosing and translational metrics. For a translational perspective and clinical outlook, compare with "Unlocking Translational Potential with ω-Agatoxin IVA TFA...", noting that this dossier focuses specifically on preclinical efficacy and limitations.

Applications, Limits & Misconceptions

ω-Agatoxin IVA TFA is primarily used as a Cav2.1 calcium channel inhibitor in neuronal calcium current recording, synaptic transmission research, epilepsy animal models, and neuroprotection studies. Its selectivity and potency enable precise interrogation of Cav2.1-dependent processes.

Common Pitfalls or Misconceptions

• ω-Agatoxin IVA TFA does not block L-type or T-type calcium channels at any tested concentration (Yalcin Inan et al., 2024).
• Partial N-type (Cav2.2) inhibition only occurs at high (1 μM) concentrations and is incomplete (APExBIO).
• Long-term solution stability is poor; use freshly prepared solutions due to peptide degradation (APExBIO).
• Therapeutic effects are dose-dependent and can be lost outside validated concentration ranges.
• Does not affect seizure models not involving Cav2.1 channelopathy or calcium-dependent neurotransmitter release.

Workflow Integration & Parameters

For in vitro experiments, ω-Agatoxin IVA TFA is typically applied at 100 nM–1 μM to brain slices or cultured neurons for calcium current or synaptic transmission recording. In animal models, effective doses are 0.01–1 nM (intracerebroventricular) for acute seizure models and 0.1–0.5 nM (intraperitoneal) for kindling paradigms (Yalcin Inan et al., Methods). The compound should be stored at –20°C under nitrogen, protected from moisture and light. Long-term solution storage is discouraged; prepare fresh aliquots for each experiment (APExBIO). For detailed workflows and troubleshooting, users may consult "ω-Agatoxin IVA TFA: Precision Disruption of Cav2.1 Signal...", which provides expanded protocol guidance for synaptic and epilepsy studies. APExBIO (C8722) offers validated product quality and technical documentation for reproducible research.

Conclusion & Outlook

ω-Agatoxin IVA TFA is a rigorously validated, highly selective Cav2.1 channel inhibitor with nanomolar potency and proven neuroprotective, anticonvulsant effects in preclinical models. Its use enables precise dissection of calcium-dependent neuronal signaling, apoptosis, and plasticity. Ongoing research may extend its applications to diverse models of neurodegeneration, synaptic physiology, and translational therapeutics. For molecular mechanism, dosing, and the latest performance benchmarks, researchers are encouraged to reference both the APExBIO product page and recent peer-reviewed literature.